|
|
|
27.10.25 - 03:57
|
Health Canada Grants Authorization for Leqembi® (lecanemab) (PR Newswire)
|
|
|
STOCKHOLM, Oct. 26, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Leqembi® (lecanemab) for the treatment of adult patients with a clinical diagnosis of......
|
|
|
17.10.25 - 15:01
|
BioArctic presents Nomination Committee (Cision)
|
|
|
Stockholm, Sweden, October 17, 2025 – Pursuant to the instruction regarding the appointment of the Nomination Committee, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) shall have a Nomination Committee comprising one representative for each of the three principal shareholders in terms of votes, based on the information received from Euroclear Sweden AB on the last banking day in September 2025, as well as the Chairman of the Board (convener).
September 30, 2025, the three largest shareholders were Demban AB, Ackelsta AB and The Fourth Swedish National Fund (Fjärde AP-fonden).
The three...
|
|
|
14.10.25 - 09:33
|
First patient treated with Leqembi® (lecanemab) in the Nordics (PR Newswire)
|
|
|
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi has now been made available at a private clinic in Finland and that the first patient has started treatment. BioArctic copromotes Leqembi with its partner Eisai in the......
|
|
|
|
|
|
|
|
|
|
|
01.10.25 - 09:06
|
AKTIONÄR-Hot-Stock BioArctic: Nächste Zulassungen (Der Aktionaer)
|
|
|
Das neuartige Alzheimer-Medikament Leqembi (Lecanemab) steht immer mehr Menschen rund um den Globus zur Verfügung. Fortan darf das Mittel auch in Australien und in einer weiteren Darreichungsform in China von der japanischen Eisai und dem US-Biotech-Konzern Biogen vertrieben werden....
|
|
|
29.09.25 - 08:42
|
Leqembi® approved for IV maintenance treatment in China (PR Newswire)
|
|
|
STOCKHOLM, Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treatment of early Alzheimer's disease by the National......
|
|
|
29.09.25 - 08:39
|
Leqembi® approved for IV maintenance treatment in China (PR Newswire)
|
|
|
STOCKHOLM, Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treatment of early Alzheimer's disease by the National......
|
|
|
|
|
|
|
|
|
09.09.25 - 09:06
|
Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 (Cision)
|
|
|
Stockholm, Sweden, September 9, 2025 – Uppsala University announced today that BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) CEO, Gunilla Osswald, has been awarded the title Alumnus of the Year 2025 in recognition of her career, reflecting the university's values: scientific excellence, importance to society and innovation.
The motivation reads: As a business leader, she is visionary and inclusive. She creates a shared sense of purpose, a strong feeling of meaning, and a culture characterized by collaboration—both within the organization and in dialogue with external partners. Gunilla...
|
|
|
03.09.25 - 23:48
|
Lars Lannfelt and Pär Gellerfors divest class B shares in BioArctic (Cision)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
PLEASE...
|
|
|
|
|
03.09.25 - 17:36
|
Lars Lannfelt and Pär Gellerfors announce their intention to divest parts of their respective shareholdings in BioArctic (Cision)
|
|
|
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SWTIZERLAND OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY, NOR SHALL THERE BE ANY SALE OF THE SECURITIES REFERRED TO HEREIN, IN OR INTO ANY JURISDICTION WHERE SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
PLEASE...
|
|
|
|
|
|
|
01.09.25 - 18:30
|
Number of shares and votes in BioArctic AB (publ) as of August 29, 2025 (Cision)
|
|
|
Stockholm, September 1, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 106,000 Class B shares during August for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 106,000 options of series 2019/2028.
As of August 29, 2025, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,637,485 shares, of which 74,237,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
